What are the NCCN treatment guidelines for surgically unresectable locoregional gastric cancer?

Updated: Feb 23, 2021
  • Author: Elwyn C Cabebe, MD; Chief Editor: N Joseph Espat, MD, MS, FACS  more...
  • Print

For surgically unresectable locoregional disease, NCCN recommendations are as follows:

  • Chemoradiation  or
  • Systemic therapy  or
  • Palliative management

For metastatic gastric cancer, the NCCN recommends palliative chemotherapy or entry into a clinical trial. [4]

For systemic therapy, NCCN recommendations are as follows:

  • Perioperative chemotherapy - Preferred regimens are FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel [Taxotere]) (category 1) and a fluoropyrimidine plus oxaliplatin
  • Preoperative chemoradiation - Infusional fluorouracil can be replaced with capecitabine
  • Postoperative chemoradiation in patients who received less than a D2 lymph node dissection  - Infusional fluorouracil or capecitabine before and after fluoropyrimidine-based chemoradiation
  • Postoperative chemoradiation in patients who have undergone primary D2 lymph node dissection - Preferred regimens are capecitabine and oxaliplatin (category 1) and fluorouracil and oxaliplatin
  • Chemoradiation for unresectable disease - Preferred Regimens are fluorouracil (or capecitabine) and either oxaliplatin or cisplatin

For description of chemotherapy and chemoradiotherapy regimens, see Gastric Cancer Treatment Protocols.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!